(Q38321861)

2 September 2017

1 reference

title

Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer (English)

1 reference

2 September 2017

1 reference

1

1 reference

2 September 2017

James A Eastham

2

1 reference

2 September 2017

14 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

33

1 reference

2 September 2017

5

1 reference

2 September 2017

217-225

1 reference

2 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Prostate cancer, version 2.2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Changing nature of high risk patients undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Preoperative versus postoperative chemoradiotherapy for rectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk local

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.11.020

10.1016/J.UROLONC.2014.11.020

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25596644